288 related articles for article (PubMed ID: 10473092)
21. Cellular distribution and clinical value of urokinase-type plasminogen activator, its receptor, and plasminogen activator inhibitor-2 in esophageal squamous cell carcinoma.
Shiomi H; Eguchi Y; Tani T; Kodama M; Hattori T
Am J Pathol; 2000 Feb; 156(2):567-75. PubMed ID: 10666386
[TBL] [Abstract][Full Text] [Related]
22. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
De Vries TJ; Mooy CM; Van Balken MR; Luyten GP; Quax PH; Verspaget HW; Weidle UH; Ruiter DJ; Van Muijen GN
J Pathol; 1995 Jan; 175(1):59-67. PubMed ID: 7891228
[TBL] [Abstract][Full Text] [Related]
23. Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis.
Ohba K; Miyata Y; Kanda S; Koga S; Hayashi T; Kanetake H
J Urol; 2005 Aug; 174(2):461-5. PubMed ID: 16006865
[TBL] [Abstract][Full Text] [Related]
24. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
Li H; Dong S; Zeng Y
Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
[TBL] [Abstract][Full Text] [Related]
25. The expression of plasminogen activator system in a rat model of periodontal wound healing.
Xiao Y; Li H; Bunn C; Bartold PM
J Periodontol; 2001 Jul; 72(7):849-57. PubMed ID: 11495131
[TBL] [Abstract][Full Text] [Related]
26. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis.
Sugiura Y; Ma L; Sun B; Shimada H; Laug WE; Seeger RC; DeClerck YA
Cancer Res; 1999 Mar; 59(6):1327-36. PubMed ID: 10096567
[TBL] [Abstract][Full Text] [Related]
27. Immunohistochemical detection of uPA, uPAR, PAI-1, and maspin in ameloblastic tumors.
Kumamoto H; Ooya K
J Oral Pathol Med; 2007 Sep; 36(8):488-94. PubMed ID: 17686008
[TBL] [Abstract][Full Text] [Related]
28. Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study.
Takeuchi Y; Nakao A; Harada A; Nonami T; Fukatsu T; Takagi H
Am J Gastroenterol; 1993 Nov; 88(11):1928-33. PubMed ID: 8237943
[TBL] [Abstract][Full Text] [Related]
29. [Influence of overexpressed coagulant and fibrolytic components in tumor tissues on the prognosis of non-small cell lung cancer].
Chen WH; Wang C; Zhang YH; Yang YH; Zhan HY; Zhang LM
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(45):3228-32. PubMed ID: 18399120
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and secretion of plasminogen activators and plasminogen activator inhibitors in cell lines of different groups of human lung tumors.
Heidtmann HH; Hofmann M; Jacob E; Erbil C; Havemann K; Schwartz-Albiez R
Cancer Res; 1989 Dec; 49(24 Pt 1):6960-5. PubMed ID: 2555056
[TBL] [Abstract][Full Text] [Related]
31. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
32. Expression analysis and RNA localization of PAI-RBP1 (SERBP1) in epithelial ovarian cancer: association with tumor progression.
Koensgen D; Mustea A; Klaman I; Sun P; Zafrakas M; Lichtenegger W; Denkert C; Dahl E; Sehouli J
Gynecol Oncol; 2007 Nov; 107(2):266-73. PubMed ID: 17698176
[TBL] [Abstract][Full Text] [Related]
33. Increased expression of matrix metalloproteinases (MMP)-2, MMP-9, and the urokinase-type plasminogen activator is associated with progression from benign to advanced ovarian cancer.
Schmalfeldt B; Prechtel D; Härting K; Späthe K; Rutke S; Konik E; Fridman R; Berger U; Schmitt M; Kuhn W; Lengyel E
Clin Cancer Res; 2001 Aug; 7(8):2396-404. PubMed ID: 11489818
[TBL] [Abstract][Full Text] [Related]
34. The plasminogen activator system in pancreas cancer: role of t-PA in the invasive potential in vitro.
Paciucci R; Torà M; Díaz VM; Real FX
Oncogene; 1998 Feb; 16(5):625-33. PubMed ID: 9482108
[TBL] [Abstract][Full Text] [Related]
35. Expression and prognostic significance of urokinase and plasminogen activator inhibitor type-1 in endometrial hyperplasia and cancer.
Taponeco F; Curcio C; Giuntini A; Nardini V; Fornaciari G; Artini PG; D'Ambrogio G; Genazzani AR
J Exp Clin Cancer Res; 2001 Jun; 20(2):239-46. PubMed ID: 11484981
[TBL] [Abstract][Full Text] [Related]
36. Elevated levels of urokinase-type plasminogen activator and plasminogen activator inhibitor type-1 in malignant human brain tumors.
Landau BJ; Kwaan HC; Verrusio EN; Brem SS
Cancer Res; 1994 Feb; 54(4):1105-8. PubMed ID: 8313368
[TBL] [Abstract][Full Text] [Related]
37. Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas.
Foca C; Moses EK; Quinn MA; Rice GE
Gynecol Oncol; 2000 Nov; 79(2):244-50. PubMed ID: 11063652
[TBL] [Abstract][Full Text] [Related]
38. Expression of urokinase, plasminogen activator inhibitors and urokinase receptor in pregnant rhesus monkey uterus during early placentation.
Feng Q; Liu Y; Liu K; Byrne S; Liu G; Wang X; Li Z; Ockleford CD
Placenta; 2000; 21(2-3):184-93. PubMed ID: 10736241
[TBL] [Abstract][Full Text] [Related]
39. Factors involved in the plasminogen activation system in human breast tumours.
Damjanovich L; Turzó C; Adány R
Thromb Haemost; 1994 Jun; 71(6):684-91. PubMed ID: 7974332
[TBL] [Abstract][Full Text] [Related]
40. Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions.
Bolon I; Brambilla E; Vandenbunder B; Robert C; Lantuejoul S; Brambilla C
Lab Invest; 1996 Jul; 75(1):1-13. PubMed ID: 8683934
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]